Developing Next Generation Gene Therapy Vectors for the Treatment Of Rare Genetic Diseases

Time: 9:30 am
day: Day One


  • Capsid, transgene, and process optimization for AAV gene therapy candidates
  • Assessing process and product quality impact on potency, kinetics, and durability
  • Selecting appropriate ex vivo and in vivo models to predict clinical safety and translatability